MJN110

SKU: orb1301465

Description

MJN110 is a potent and selective inhibitor of monoacylglycerol lipase (MAGL) with an IC50 of 9.1 nM. This compound demonstrates opioid-sparing effects in murine neuropathic pain models, supporting its use in research on endocannabinoid signaling, pain mechanisms, and potential analgesic development in both in vitro and in vivo studies.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1438416-21-7
• MW: 462.33
• Purity: 99.41% (May vary between batches)
• Formula: C₂₂H₂₁Cl₂N₃O₄
• SMILES: Clc1ccc(cc1)C(N1CCN(CC1)C(=O)ON1C(=O)CCC1=O)c1ccc(Cl)cc1
• Target: MAGL,Lipase
• Solubility: DMSO:27.5 mg/mL (59.48 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.33 mM)

Bioactivity

• Target IC50:
  MAGL:9.1 nM
• In Vivo:
  The Selective Monoacylglycerol Lipase Inhibitor Cravatt Reagent Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
• Animal Research:
  For repeated administration experiments, mice were given vehicle, 0.0818 mg/kg MJN110, 0.469 or 10 mg/kg morphine, or a combination of 0.0818 mg/kg Cravatt Reagent and 0.469 mg/kg morphine twice daily for 5.5 days. Then, mice underwent behavioral testing on day 6. The combination of 0.0818 mg/kg MJN110 and 0.469 mg/kg morphine produced significant antinociceptive effects.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, MJN 110, MJN110, MJN-110, MAGL, Monoacylglycerol lipase, Inhibitor, Cravatt Reagent

Compound Identifiers

PubChem CID

71722059